Drug Trial Radar · NCT05930561
4D-150 in Patients With Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Aug 9, 2023
Primary completion
Feb 28, 2029
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- 4D Molecular TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
Conditions
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
4D-150 IVTBiological
4D-150: AAV-based gene therapy comprised of miRNA targeting VEGF-C and codon-optimized sequence encoding aflibercept.
Aflibercept IVTBiological
Commercially available Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of TEAEs and SAEs, including clinically significant changes in safety parameters (Part 1)Time frame: 60 months
- Annualized number of aflibercept injections in the study eye (Part 2)Time frame: 52 weeks
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Verum Research, LLC
Eugene, Oregon
Erie Retina Research
Erie, Pennsylvania
Austin Clinical Research
Austin, Texas
Piedmont Eye Center
Lynchburg, Virginia
Emanuelli Research and Development Center
Arecibo, Puerto Rico, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.